One saving grace that Generex / NGIO has is that their technology has the ability to be used not just with Covid but with a wide range of diseases like cancer, swine flu and a host of others.

We have seen the paper on Cancer, so the success there is proven. There is now a swine flu problem and who knows what else is coming around the corner. So, they are in a unique position to go outside Covid and advance into other areas quickly. That is where this China deal is so critical among other things.

And that is why it really needs to be discussed in my view even moreso.